Delving into the Latest Updates on LIN-2102 with Synapse

Overview

Basic Info

Drug Type

Nanobody

Synonyms

LIN 2102, LIN2102, SLN12140

Target

complement factor

Action

inhibitors

Mechanism

complement factor inhibitors(Complement Factor inhibitors)

Therapeutic Areas

Immune System DiseasesCongenital DisordersEye Diseases+ [1]

Active Indication

Glomerulonephritis, IGAAcute Kidney Injurydry age-related macular degeneration

Inactive Indication-

Originator Organization

Linno Pharmaceuticals Inc.

Active Organization

Linno Pharmaceuticals Inc.

Inactive Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

[Translation] A randomized, double-blind, placebo-controlled Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SLN12140 in healthy participants with single subcutaneous/intravenous dose escalation and multiple subcutaneous injections

主要目的：评价 SLN12140在健康参与者中单次皮下注射/静脉输注注射或多次皮下注射给药的安全性、耐受性；次要目的：评价 SLN12140在健康参与者中单次皮下注射/静脉输注注射或多次皮下注射给药的药代动力学特征、药效学指标特征以及免疫原性

[Translation]

Primary purpose: To evaluate the safety and tolerability of SLN12140 administered by single subcutaneous injection/intravenous infusion or multiple subcutaneous injections in healthy participants; Secondary purpose: To evaluate the pharmacokinetic characteristics, pharmacodynamic index characteristics and immunogenicity of SLN12140 administered by single subcutaneous injection/intravenous infusion or multiple subcutaneous injections in healthy participants

Start Date-

Sponsor / Collaborator

Linno Pharmaceuticals Inc.

100 Clinical Results associated with LIN-2102

Login to view more data

100 Translational Medicine associated with LIN-2102

Login to view more data

100 Patents (Medical) associated with LIN-2102

Login to view more data

100 Deals associated with LIN-2102

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Glomerulonephritis, IGA	Phase 1	China	Linno Pharmaceuticals Inc.	14 Apr 2025
Acute Kidney Injury	IND Application	China	Linno Pharmaceuticals Inc.	-
dry age-related macular degeneration	Preclinical	China	Linno Pharmaceuticals Inc.	07 May 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data